Trapp Johannes, Jochum Anne, Meier Rene, Saunders Laura, Marshall Brett, Kunick Conrad, Verdin Eric, Goekjian Peter, Sippl Wolfgang, Jung Manfred
Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104 Freiburg, Germany.
J Med Chem. 2006 Dec 14;49(25):7307-16. doi: 10.1021/jm060118b.
NAD+-dependent histone deacetylases, sirtuins, cleave acetyl groups from lysines of histones and other proteins to regulate their activity. Identification of potent selective inhibitors would help to elucidate sirtuin biology and could lead to useful therapeutic agents. NAD+ has an adenosine moiety that is also present in the kinase cofactor ATP. Kinase inhibitors based upon adenosine mimesis may thus also target NAD+-dependent enzymes. We present a systematic approach using adenosine mimics from one cofactor class (kinase inhibitors) as a viable method to generate new lead structures in another cofactor class (sirtuin inhibitors). Our findings have broad implications for medicinal chemistry and specifically for sirtuin inhibitor design. Our results also raise a question as to whether selectivity profiling for kinase inhibitors should be limited to ATP-dependent targets.
烟酰胺腺嘌呤二核苷酸(NAD⁺)依赖性组蛋白去乙酰化酶,即沉默调节蛋白,可从组蛋白和其他蛋白质的赖氨酸上切割乙酰基以调节其活性。鉴定强效选择性抑制剂将有助于阐明沉默调节蛋白生物学,并可能产生有用的治疗药物。NAD⁺具有一个腺苷部分,该部分也存在于激酶辅因子ATP中。基于腺苷模拟的激酶抑制剂因此也可能靶向NAD⁺依赖性酶。我们提出了一种系统方法,使用来自一种辅因子类(激酶抑制剂)的腺苷模拟物作为在另一种辅因子类(沉默调节蛋白抑制剂)中生成新先导结构的可行方法。我们的发现对药物化学具有广泛影响,特别是对沉默调节蛋白抑制剂的设计。我们的结果还提出了一个问题,即激酶抑制剂的选择性分析是否应仅限于ATP依赖性靶点。